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Modeling the effects of hyaluronic 
acid degradation on the regulation 
of human astrocyte phenotype 
using multicomponent 
interpenetrating polymer networks 
(mIPNs)
Andrea C. Jimenez‑Vergara1, Rachel Van Drunen2, Tyler Cagle2 & Dany J. Munoz‑Pinto1,2,3*
Hyaluronic acid (HA) is a highly abundant component in the extracellular matrix (ECM) and a 
fundamental element to the architecture and the physiology of the central nervous system (CNS). 
Often, HA degradation occurs when an overreactive inflammatory response, derived from tissue 
trauma or neurodegenerative diseases such as Alzheimer’s, causes the ECM in the CNS to be 
remodeled. Herein, we studied the effects of HA content as a key regulator of human astrocyte (HAf) 
reactivity using multicomponent interpenetrating polymer networks (mIPNs) comprised of Collagen 
I, HA and poly(ethylene glycol) diacrylate. The selected platform facilities the modulation of HA 
levels independently of matrix rigidity. Total astrocytic processes length, number of endpoints, the 
expression of the quiescent markers: Aldehyde Dehydrogenase 1 Family Member L1 (ALDH1L1) and 
Glutamate Aspartate Transporter (GLAST); the reactive markers: Glial Fibrillary Acidic Protein (GFAP) 
and S100 Calcium‑Binding Protein β (S100β); and the inflammatory markers: Inducible Nitric Oxide 
Synthase (iNOS), Interleukin 1β (IL‑1β) and Tumor Necrosis Factor Alpha (TNFα), were assessed. 
Cumulatively, our results demonstrated that the decrease in HA concentration elicited a reduction 
in the total length of astrocytic processes and an increase in the expression of HAf reactive and 
inflammatory markers.
Astrocytes are integral to the central nervous system (CNS)  tissue1. They provide nutrients to neurons and sup-
port neural functions including axonal guidance, synaptic support, and maintenance of the blood brain  barrier2–6. 
In vivo, astrocytes exhibit a star-like morphology with small cells bodies and radial branched  processes7,8 whose 
tendrils extend to wrap around nearby neurons, providing structural support to the CNS tissue architecture. 
Furthermore, astrocytes are responsible for the deposition of extracellular matrix (ECM) components and the 
remodeling of the microenvironment surrounding CNS cells.
Once considered to play only a minor role as “helper cells” in the CNS, astrocytes have become the focus of 
numerous studies due to their role in the onset and progression of several neurodegenerative diseases such as 
Alzheimers’ disease (AD) and Parkinson’s disease. Moreover, astrocytes are key players during the inflammatory 
response and healing process of damaged nervous tissue. Astrocytes adopt a reactive phenotype in response to 
CNS tissue damage,  trauma9, or the abnormal presence of ECM structures such as amyloid beta (Aβ) plaques and 
tau  entanglements10,11. The transition from quiescent to reactive astrocytes can be characterized by monitoring 
changes in cell morphology and the relative expression of Glial Fibrillary Acidic Protein (GFAP), Aldehyde Dehy-
drogenase 1 Family Member L1 (ALDH1L1), Aldolase C (AldoC), Glutamate Aspartate Transporter (GLAST), 
and S100 Calcium-Binding Protein β (S100β) among  others12,13.
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The change from the quiescence state of astrocytes to a reactive phenotype propagates the degradation and 
removal of abnormal ECM components, dead cells, and cell debris facilitating healing by remodeling the micro-
environment of the damaged  tissue1,14. In the CNS, the microenvironment is characterized by a dynamic, delicate 
and bidirectional set of interactions between CNS cells and the ECM components. Macromolecules such as: 
Collagen Type IV (ColIV), hyaluronic acid (HA), and laminin characterize the ECM landscape of the  CNS15,16. 
These main components contribute to the regulation of normal astrocyte function and the modulation of their 
 phenotype17–19. Following tissue damage or cell death due to accumulation of Aβ or tissue trauma, the sur-
rounding ECM is degraded by the enzymatic action of metalloproteases (MMPs) and hyaluronidases initially 
secreted by microglial  cells20,21. During this process, the degradation of tissue modulates the relative content 
and identity of the main ECM components. Alterations of the ECM components combined with the release of 
ECM fragments increases the inflammatory response of microglia and contributes to the acquisition of a reactive 
astrocytic  phenotype22. This process escalates the production and activity of MMPs and hyaluronidases creating 
a vicious cycle whereby the inflammatory response promotes the over-degradation of damaged tissue. Continu-
ous degradation of the ECM alters its viscoelastic properties producing attenuated mechanical integrity and 
therefore a reduction in the microenvironment rigidity. On the other hand, scar tissue which is rich in collagen, 
fibronectin and  laminin23 deposited by fibroblast or endothelial cells can augment tissue rigidity in the damaged 
area. Vicissitudes in ECM composition and the alterations to viscoelastic properties of damaged tissue are well 
known as significant modulatory factors of  astrogliosis24.
To study key characteristics of the function and interactions between astrocytes and ECM components in the 
CNS, in vitro platforms have typically been established using 2D microenvironments. These 2D environments, 
however, do not accurately resemble the viscoelastic properties of CNS tissue nor do they capture the 3D cell 
milieu of native tissue. Moreover, findings from 2D studies cannot be easily extrapolated to the behavior of cells 
in 3D  contexts25. In fact, the behavior of astrocytes and their impact on other CNS cells in 2D culture strongly 
diverges from that seen in a 3D  culture26. Other studies have found that 2D culture platforms promote astrocyte 
 activation27 whereas 3D culture platforms are capable of sustaining astrocytes in their quiescent  state8,28.
To fabricate a 3D in vitro culture model to study the behavior of CNS cells, research efforts have focused on 
bioinspired hydrogels that recapitulate some of the key biochemical cues for the main ECM constituents in the 
 CNS29,30. Both natural and synthetic materials have been utilized to mimic the 3D landscape of CNS tissue. For 
instance, Collagen Type I (ColI) has been used as the foundational component of engineered scaffolds due to 
its self-assembly properties, similar chemical composition to ColIV, and its capacity to promote the spreading 
and cell growth of CNS  cells8,31–33. Given its high presence in CNS tissue, other approaches have employed HA-
based materials for the fabrication of engineered  scaffolds8,34. Natural based polymer scaffolds also provide great 
biochemical compatibility. However, natural polymers alone are not sufficient to withstand the physiological 
pressure induced by cellular proliferation, spreading, and cell-mediated  degradation35,36.
To address this challenge, we used a multicomponent interpenetrating polymer network (mIPN) system 
comprised of ColI, HA, and poly(ethylene glycol) diacrylate (PEGDA). The mIPN fabrication, mechanical char-
acterization and initial evaluation of their cytocompatibility (≥ 84%) for cells in CNS was previously described 
by Van Drunen et al.33. ColI and HA were employed to promote cell attachment, spreading, and ECM mediated 
signaling. Linear PEGDA was used to tune the mechanical performance of the engineered scaffold to closely 
match the complex modulus of mouse brain cortex tissue (≈ 6.9 kPa) and to maintain the physical integrity of 
the  scaffolds33.
Herein our research team utilized this scaffold platform to investigate the effects of HA degradation on the 
regulation of human astrocyte phenotype independently of matrix rigidity. As CNS tissue degrades by MMPs 
and hyaluronidases, the content of HA high molecular weight (HA-HMW)  decreases37,38. In this work, we evalu-
ated the changes in astrocyte phenotype at the gene and protein expression levels as a function of the decrease 
in HA-HMW content. Astrocyte responses to different HA-HMW concentration were monitored in terms of 
cell spreading; the expression of the quiescent markers: ALDH1L1, and GLAST; the reactive makers GFAP, and 
S100β; and the inflammatory markers interleukin 1β (IL-1β), inducible nitric oxide synthase (iNOS), and tumor 
necrosis factor alpha (TNFα). In addition, the expression of the Homing Cell Adhesion Molecule (HCAM or 
CD44), a cell receptor for HA was evaluated at the protein expression level. Three mIPN formulations contain-
ing 2 mg/mL, 1 mg/mL, and 0 mg/mL of HA-HMW and exhibiting a complex modulus between 6.4 kPa and 
7.4 kPa were employed (Table1).
In this work, we demonstrated that the reduction in HA-HMW content in the proposed scaffolds attenu-
ates astrocyte spreading and the quantity of cell processes. In addition, the expression of the selected quiescent 
markers decreases as HA-HMW is reduced in the engineered matrix. Furthermore, the expression of the reac-
tive phenotype markers and inflammatory cytokines increases in the low HA-HMW containing mIPNs. We 
demonstrated that the reduction in HA-HMW concentration—which is associated with HA degradation—is a 
Table 1.  Composition and complex modulus of mIPNs.
mIPN ColI (mg/mL) HA (mg/mL)
PEGDA molecular weight 
(kDa)
PEGDA final concentration 
(%w/w) Complex modulus (kPa)
0 mg/mL HA 3.0 0.0 10.0 7.0 7.4 ± 0.3
1 mg/mL HA 3.0 1.0 3.4 7.0 6.8 ± 1.9
2 mg/mL HA 3.0 2.0 3.4 7.5 6.4 ± 0.9
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significant contributing factor to the modulation of human astrocyte phenotype. Specifically, the reduction of 
HA-HMW promotes astrocyte reactivity and their inflammatory responses.
Materials and methods
PEGDA and photoinitiator synthesis. Linear PEG (3.4 or 10.0 kDa, Sigma) was reacted in anhydrous 
dichloromethane (Sigma) with acryloyl chloride (Sigma) using 4:1 (3.4 kDa) or 8:1 (10.0 kDa) molar ratio rela-
tive to PEG. Trimethylamine (Sigma) was added to the reaction mixture using a 2:1 molar ratio. The reaction 
was carried out at 4 °C and the reaction product was purified as previously  described39. The substitution level of 
hydroxyl groups was confirmed to reach ≈ 95% by 1H NMR.
Lithium phenyl-2,4,6-trimethylbenzoylphosphinate (LAP) was selected as the photoinitiator for the PEGDA 
polymerization. This photoinitiator was synthesized as previously described by Fairbanks et al.40. In brief, 3.0 g 
of dimethyl phenylphosphonite (Alfa Aesar) were mixed with 3.2 g of 2,4,6-trimethylbenzoyl chloride (Alfa 
Aesar) under nitrogen. After 18 h of stirring at room temperature the reaction mixture was mixed with 6.1 g 
of lithium bromide (Acros Organics) in 100 mL of 2-butanone (Fisher). The resulting solution was heated at 
50 °C for 10 min and allowed to rest for four hours at room temperature. The formed solid was filtered, rinsed 
with 2-butanone under vacuum three times and dried under vacuum. LAP was characterized by 1H NMR. The 
resulting LAP was dissolved in water to a concentration of 100 mM.
Cells encapsulation. Primary human astrocytes (HAf, Cell Applications) at passage 4 were expanded in 
monolayer and cultured in DMEM/F12 50:50 (Corning) medium supplemented with 10% FBS (Atlanta biologi-
cals), 1% Glutamax (Gibco) and 1% PS (Gibco). Cells were maintained at 37 °C and 5%  CO2 prior to encapsula-
tion.
At passage 5, HAf were harvested and encapsulated at 8.0 × 105 cells/mL in mIPN formulations contain-
ing constant levels of ColI (3 mg/mL) and 0, 1 or 2 mg/mL of HA-HMW and appropriate levels of 3.4 kDa or 
10.0 kDa PEGDA (Fig. 1) to achieve materials with similar complex modulus (Table 1). The mIPN formula-
tions were selected based on the mechanical properties previously screened and published by our  laboratory33. 
In brief, HA-HMW (Lifecore Biomedical, 1.35–1.38 MDa) at the desired concentration was dissolved in an 
aqueous neutralization solution containing NaOH and 10X PBS. Ice-cold high-concentration rat tail ColI (BD 
Bioscences, 9.66 mg/mL in 0.02 N acetic acid) was then diluted to 3 mg/mL in the cold neutralization solution. 
The HAf were resuspended in the neutralized ice-cold solution. Three hundred microliters of the cell suspension 
were then pipetted into BD Falcon culture inserts (12 mm diameter, 8 μm pore size). The constructs were then 
incubated for 30 min at 37 °C, 5%  CO2 and 95% relative humidity. During this incubation period, the collagen 
was allowed to crosslink resulting in the formation of the first polymer network containing physically entrapped 
HA-HMW molecules. The resulting ColI-HA gels were then immersed in phenol-red free DMEM/F12 50:50 
(Hyclone) supplemented with 10% FBS, 1% PS and HA-HMW at the same concentration as in the ColI-HA 
gels. Cells were allowed to spread for 4 h in the ColI-HA constructs prior to the immersion of the constructs 
in the corresponding PEGDA precursor solution. After 4 h, the media was carefully replaced with 1.7 mL of 
sterile-filtered PEGDA precursor solution in phenol-red free DMEM/F12 50:50 supplemented with 5% FBS, 1% 
PS, HA-HMW and, 1% v/v of LAP as reported in (Table 1). The PEGDA solution was allowed to permeate the 
structure of the ColI-HA gel for 4 h while incubated at 37 °C with 5%  CO2. Afterwards, the excess of PEGDA 
solution was removed. The constructs were then exposed to long wave UV for 5 min (Spectroline, = 6 mW/cm2, 
365 nm). The selected mIPNs formulations contain different concentrations of HA-HMW while maintaining 
similar complex modulus within the range of the elastic properties of brain cortex  tissue33,41,42.
For each mIPN formulation, the resulting hydrogels were divided in three groups: 0, 3 and 10 days. The mIPNs 
were cultured in DMEM/F12 supplemented with 10% FBS and 1% PS at 37 °C, 5%  CO2 and 95% relative humid-
ity. Six independent samples per group were collected at each corresponding time point. Zero-day samples were 
fixed with 10% buffered formalin and stored in the fixative solution at 4 °C until use. The zero-day samples were 
used for the spreading analysis. Day 3 and day 10 constructs were split in two during the sample collection. One 
part from each sample was fixed and stored in the fixative solution at 4 °C until use. The fixed samples from day 
3 and day 10 were used for cytological analyses. The other half from each specimen was snap-frozen and stored 
at − 80 °C for gene expression assessments.
Cell viability. The fabrication process of the mIPNs involves the use of UV radiation during the polymeri-
zation of the PEGDA. Therefore, to assess the effects of the fabrication process on cell viability, the Live/Dead 
assay (Invitrogen, Life Technologies) was performed 24 h post hydrogel fabrication. Samples were collected and 
images from samples specimens were taken following the process described by Munoz-Pinto et al.36.
Hydrogel mechanical characterization. The viscoelastic properties of the mPINs were measured 
by dynamic mechanical analysis (DMA) using a TA Instruments Electroforce 3100 mechanical tester. Four 
independent specimens per mIPN formulation of approximately 8 mm in diameter and 1 mm in height were 
preloaded with a 2 g force and exposed to oscillations of 100 μm in amplitude at 1 Hz of frequency. The storage 
(Eʹ) and loss (Eʺ) moduli were recorded and the complex modulus  (E*) calculated as E∗ =
√
E′2 + E′′2.
Cell morphology measurements. Confocal microscopy imaging. Approximately 1 mm transverse sec-
tions from the 0 day time point were cut manually and fixed with formalin. The sample slices were washed with 
PBS 3 times and stained with Rhodamine Phalloidin (Life technologies, 1:100) and DAPI dilactate (4′,6-diamid-
ino-2-phenylindole, Life technologies, 300 nM). Following overnight incubation at 4 °C, the slices were washed 
with PBS three times and placed in a 35 mm glass bottom dish surrounded by a small amount of PBS to prevent 
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dehydration during the imaging process. Images were acquired using a Nikon A1 confocal microscope system 
equipped with a 20X objective. Three regions per sample were randomly selected for imaging and six to seven 
consecutive images in the z direction were taken per region.
Cell morphology analysis. The total branch length and the number of endpoints were assessed using ImageJ2 
(Fiji) and a modified protocol developed by Young et al.43. In brief, 6 to 7 consecutive images with an optical 
thickness of 25 μm from each region in the hydrogel were stacked to generate z-stack projection image. A skel-
eton was generated from the stack projection. Branch length and number of endpoints were calculated using 
the plugin AnalyzeSkeleton (2D/3D). To illustrate this analysis, a raw image of a cell and its skeleton projection 
highlighting the cell center and branch length have been included in the Supplementary Fig. 1. Four independ-
ent specimens per experimental group containing between 50 and 130 cells in each 3D projection were analyzed.
Extraction of mRNA and gene expression evaluation. The astrocyte phenotype was evaluated after 
3 and 10 days in culture using qRT-PCR. For each time point, the relative expression of each selected maker was 
normalized relative to the 0 mg/mL HA mIPN group. The mRNA from 4–6 independent samples per group was 
extracted using the Dynabeads mRNA direct kit (Ambion, Life Technologies) as described by Jimenez-Vergara 
et al.44. The purified polyA-mRNA was stored at − 80 °C until use.
Gene expression evaluation of HAf was performed using a 7500 Real-Time PCR Systems (Applied Biosys-
tems) and the SuperScript III Platinum One-Step qRT-PCR kit (Invitrogen, Life Technologies). The mRNA 
levels for ALDH1L1, GLAST, GFAP, S100β, iNOS, IL-1β and tumor necrosis factor alpha TNFα genes were 
assessed in duplicate for each construct. Primer sequences are shown in Supplementary Table 1. Approximately 
15 ng of polyA-mRNA and 5 µL of 1 mM primer were added per 25 µL of reaction mixture. Changes in SYBR 
Figure 1.  Schematic representation of the fabrication of collagen-HA-PEGDA mIPN hydrogels.
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Green fluorescence was used to monitor each reaction amplification. In addition, ROX dye was used as a passive 
reference. For each sample the gene expression relative to the reference gene (β-actin) was calculated using the 
ΔΔCt method. The appropriate amplification product for each PCR reaction was verified by using the melting 
temperature curve.
Protein expression assessments. Protein expression of the markers ALDH1L1, GLAST, GFAP, S100β 
iNOS, IL-1β, TNFα and HCAM was assessed by immunostaining. Transverse section of approximately 1 mm in 
thickness were cut from each formalin fixed sample. Hydrogel sections were then blocked with PBST (PBS plus 
0.1% Tween 20) containing 3% BSA for 12 h at 4 °C. Primary antibody (Supplementary Table 2) was diluted in 
PBS containing 3% BSA and then applied to the sections overnight at 4 °C. After rinsing with PBS, the sections 
were exposed to Alexa 488 anti-Mouse (Life Technologies) and DAPI dilactate for 12 h at 4 °C. Following rinsing 
in PBS to remove unbound secondary antibody, confocal microscopy was performed using a confocal micro-
scope equipped with a 20X objective. Two randomly selected regions in each sample segment were imaged. A 
total of 5 to 16 independent images from 4 specimens per formulation were taken using an optical thickness of 
50 μm. Between 40 and 260 cells per image were analyzed.
Semi-quantitatively evaluation of immunostaining results was conducted by counting the number of cells 
stained with Alexa 488 antibody and the number of cells stained with DAPI (total cell number). Cell counting 
was performed from each image using ImageJ  software36. For each staining, the laser power, detector gain, and 
offset were maintained constant across all imaged specimens and sample groups. Fluorescence intensity for 
each stained image was quantified using ImageJ. Immunostaining intensity (d) for each image was determined 
using the equation:
Statistical analysis. Data are reported as mean ± standard deviation. Comparison of sample means was 
performed using ANOVA followed by Tukey’s post-hoc test (SPSS software). The mean and standard deviation 
was computed from at least four independent samples per experimental group. A p-value of 0.05 or less was 
considered statistically significant.
Results and discussion
Cell viability. The total cell viability for each formulation was estimated by taking the ratio between living 
cells and total cell count revealed that 24 h post fabrication about 94.0 ± 2.2%, 93.2 ± 1.5% and 94.8 ± 0.7% of cells 
were alive in the 2 mg/mL, 1 mg/mL and 0 mg/mL HA mIPN formulations respectively (Supplementary Fig. 2). 
Differences across formulations were not statistically significant (p ≥ 0.504). These viability results are similar to 
those observed for fibroblast, human adult stem cells, and CNS cells using PEGDA-based hydrogels and the UV 
polymerization  system33,40,45.
Hydrogel mechanical characterization. Viscoelastic properties play an important regulatory role in 
the progression and adoption of specific cell  phenotypes46. Therefore, to fabricate a 3D model of CNS tissue it is 
important that the mechanical performance displayed by engineered scaffolds is similar to that in native tissue. 
Cells in the CNS tissue experience a microenvironment characterized by low rigidity  values47. In this work, the 
selected mIPN system allowed us to tune the viscoelastic properties of the proposed biomaterials to be in close 
proximity to the mechanical behavior of mouse brain cortex tissue (≈ 6.9 kPa)33. Biochemical cues in the mIPNs 
were provided by the presence of constant levels of ColI (3 mg/mL) and varying levels of HA (2 mg/mL, 1 mg/
mL and 0 mg/mL). The complex modulus of the constructs was maintained within the vicinity of that in mouse 
brain cortex tissue by the use of 3.4 kDa PEGDA and 10 kDa PEGDA at 7.0% and 7.5% w/w concentration. As 
shown in Table 1, the different selected mIPNs do not display significant differences in the complex modulus 
(p ≥ 0.646) and their performance is similar to brain cortex previously reported in  literature33,41,42.
Cell morphology measurements. Achieving physiological cell morphology is one main challenge in 
culturing astrocytes for brain  research8. Cell shape is a key physiological feature that contributes to normal cell 
function and overall tissue physiology. The proposed family of mIPNs promotes the adoption of star-shaped 
morphology in human astrocytes in a 3D context. While the mechanical performance in the scaffolds was con-
sistent across each formulation, the compositions varied in terms of the HA content. To evaluate the effects of 
HA concentration in the mIPNs on astrocyte cell morphology, HAf were allowed to spread in each formulation 
for 4 h before starting the diffusion of PEGDA. The 4 h spreading time was identified as the maximum time 
the cells can be allowed to spread without significant cell-mediated bulk matrix contraction. The spreading 
time depends on cell type and matrix composition. Other studies using a similar systems including one by 
Munoz-Pinto et al. identified 6 h as an appropriate time frame to promote the spreading of human mesenchy-
mal stem cells (hMSCs) while preventing cell mediated contraction of the  scaffold36. Furthermore, Khetan et al. 
determined that 7 days in culture was sufficient to promote the spreading of hMSCs in a HA-based  matrix48. To 
highlight the changes in cell morphology as a function of time, a round control group was included. In the round 
control group, HAf were allowed to spread for just 30 min in a 0 mg/mL HA mIPN before the PEGDA infiltra-
tion and its subsequent photopolymerization. Cell morphology was then evaluated in terms of total branch 
length and number of endpoints (Fig. 2).
d =
number of cells stained × Fluoresce intensity
total cell number
.
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The results from the morphology analysis indicate an overall increase in total branch length and the num-
ber of endpoints after 4 h of spreading relative to round control group (Figs. 2, 3A,B). Most of the astrocytes 
in the control group showed round morphologies (Fig. 2) while the astrocytes that were allowed to spread for 
4 h exhibited the characteristic star shaped morphologies (Fig. 2). The total processes length was increased by 
2.1-fold in the 2 mg/mL HA mIPN, 1.6-fold in the 1 mg/mL HA mIPN and 1.4-fold in the 0 mg/mL HA mIPN 
relative to the round control group. However, the increase in total branch length (Fig. 3A) was only significantly 
different from the control group in the 2 mg/mL (p = 0.001) and 1 mg/mL (p = 0.037) mIPNs. In addition, the total 
branch length appears to decrease with the reduction in HA content. The average processes length decreases from 
23.1 µm in the 2 mg/mL HA to 17.8 µm for 1 mg/mL HA (p = 0.103) and to 15.8 µm for 0 mg/mL HA (p = 0.025) 
mIPN. Furthermore, it is important to highlight that the distribution curves for branch length of HAf allowed 
to spread for 4 h exhibited similar shape and dispersion behavior across experimental groups. The maximum 
average processes length (Fig. 3C) measured in at least one cell per image. In the 2 mg/mL mIPN the maximum 
was 80.4 µm while the maximum average processes length in the 1 mg/mL and 0 mg/mL mIPNs were 66.8 µm 
and 53.2 µm respectively. As expected the distribution in the round control group was shifted toward the left 
of the figure indicating low levels of cell spreading and round morphologies. The measured cell dimensions are 
in close agreement and within the range of recently published results for the morphological characterization of 
human astrocytes in the PEG based  hydrogels49.
Relative to the round control group, there was an increase in the total number of endpoints of 2.4-fold in 
the 2 mg/mL HA mIPN, 1.2-fold in the 1 mg/mL HA mIPN and 1.4-fold in the 0 HA mg/mL mIPN (Fig. 3B). 
Significant differences in the total number of endpoints from the round control group were identified for the 
2 mg/mL HA mIPN (p = 0.007) and 0 mg/mL HA mIPN (p = 0.035). Analysis of the number of endpoints reveal 
an apparent decrease for the 1 mg/mL HA and 0 HA mg/mL relative to 2 mg/mL HA mIPN, but statistical 
differences were not observed (p ≥ 0.634). The distribution curves for the number of endpoints shows similar 
behavior as the distribution for the total branch length. Figure 3D reveals that the maximum number endpoints 
in HAf allowed to spread for 4 h were 34 for the 2 mg/mL HA mIPN, 29 for the 1 mg/mL HA mIPN and 27 for 
the 0 mg/mL HA mIPN. Cumulatively, the morphology analysis reveals that relative to the round control group, 
the selected 4 h spreading time is sufficient to achieve significant differences in average branching length and 
total number of endpoints in HAf (Fig. 3A,B). Moreover, the total branch length and total number of endpoints is 
modulated by the reduction in HA content in the mIPNs (Fig. 3A,B). In human brain tissue, it has been reported 
that the maximum average processes length and number of branches per cell exhibited by protoplasmic astrocytes 
is approximately 98 μm in length and approximately 37 branches per  astrocyte50. In our mIPN model human 
astrocytes reach approximately 25% of the average values for processes length and average number of endpoints. 
In our platform, the reduction in cell spreading with the decrease in HA content in the mIPNs agrees with previ-
ously reported results from Placone et al.8. However, in Placone’s work the change in astrocyte shape was linked to 
both HA content and scaffold stiffness. Our study improves on previously reported literature since our proposed 
mIPN system allows for the study of the effects of HA content on human astrocyte shape independently from the 
impact of scaffold stiffness. In our 3D in vitro model, the reduction in HA content recapitulated the reduction of 
HA in natural tissue as a characteristic change during tissue injury. This model shows that the reduction in HA 
levels contributes to the loss of the characteristic and physiological morphology of human astrocytes.
Gene and protein expression analyses. Astrocytes, a fundamental CNS cell type, are characterized by 
the relative expression of several proteins which define their phenotype. Among others markers quiescent HAf 
express relatively high levels of ALDH1L1 and GLAST while protein expression of GFAP and S100β are upregu-
lated in reactive astrocytes. Additionally, markers such as iNOS, IL-1β and TNFα are also associated with reac-
tive astrocytes and contribute to the inflammatory response in CNS  tissue51,52. To study the effects of the reduc-
tion in HA content on astrocyte phenotype, samples from HAf in the mIPNs containing 2, 1 and 0 mg/mL of 
HA were collected after 3 and 10 days in culture. For each time point qRT-PCR and immunostaining analyses 
were performed targeting the quiescent markers ADLH1L1 (Fig. 4A) and GLAST (Fig. 4B), and the reactive 
markers GFAP (Fig. 4C) and S100β (Fig. 4D). The mRNA levels for the inflammatory markers iNOS, IL-1β and 
TNFα were below the detection limit. To prevent cell mediated contraction in the mIPN scaffolds during the 
cell spreading, a low cell density must be used. This experimental design limit may have restricted our ability to 
Figure 2.  Representative images of HAf spreading in mIPNs containing distinct levels of HA. The scale bar 
represents a distance of 50 µm.
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reach the appropriate levels of mRNA to accurately measure the relative expression of the selected inflammatory 
markers at the gene expression level.
Figure 3.  Average total processes length (A), average number of endpoints (B), Total processes length 
distribution (C) and number of endpoint distribution (D). *Significantly different from round control; 
#Significantly different from 2 mg/mL HA. All reported significant differences were reported for p < 0.05.
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At day 3, qRT-PCR results show approximately a 23.4% and 24.4% decrease in the expression of the quiescent 
marker ADLH1L1 for the 0 mg/mL HA and 1 mg/ml HA mIPNs formulations relative to 2 mg/ml HA group. 
However, differences in mean values across these groups are not statistically significant (p ≥ 0.353). Similarly, 
the expression of GLAST at day 10 seems to progressively decrease as HA content is reduced in the mIPNs. 
Relative to the 2 mg/mL HA mIPN, the expression of GLAST was reduced by 20.6% and 28.0% in the 1 mg/mL 
HA and 0 mg/mL HA mIPNs respectively. Differences across groups were not statistically significant (p ≥ 0.063). 
In terms of the expression of the reactive markers GFAP and S100β, no significant changes in the mean value 
were observed after 3 or 10 days in culture (p ≥ 0.109). Cumulatively, the qRT-PCR data appears to suggest that 
the reduction in HA modulates the HAf phenotype contributing to the downregulation of quiescent marker 
expression.
To complement the qRT-PCR results, protein analyses using immunostaining were performed. In contrast 
to the qRT-PCR results, immunostaining results indicate a significant impact of HA content on the modulation 
of HAf phenotype at the protein expression level. As shown in Fig. 5A,B at day 3, the relative expression levels of 
the astrocyte marker ALDH1L1 were reduced by 1.3-fold (p = 0.001) in the 1 mg/mL HA mIPN and by 2.3-fold 
(p ≤ 0.001) in the 0 mg/mL HA mIPN relative to the 2 mg/mL HA scaffold. At day 10, ALDH1L1 expression 
was also reduced with the decrease in HA concentration. The levels of ALDH1L1 in the 1 mg/mL HA formula-
tion were reduced 1.4-fold relative to the 2 mg/mL HA mIPN group (p = 0.090) while ALDH1L1 expression in 
the 0 mg/mL HA mIPN was significantly reduced by a 2.3-fold factor relative to the high HA content group 
(p = 0.001). In terms of GLAST expression (Fig. 5C,D), relative levels across experimental groups were indistin-
guishable at either day 3 (p ≥ 0.211) or day 10 (p ≥ 0.147) time points.
In addition to the evaluation of the quiescent markets ALDH1L1 and GLAST, the expression of the reactive 
markers GFAP and S100β were also evaluated at the protein level. The relative levels of GFAP were increased 
with the reduction in HA (Fig. 6A,B). The GFAP levels at day 3 (Fig. 6A) were 2.6 and 2.5-fold higher in the 
1 mg/mL (p < 0.001) and 0 mg/mL (p < 0.001) relative to 2 mg/mL HA mIPNs. After 3 days in culture, differences 
between the mean GFAP levels in the 1 mg/mL HA and 2 mg/mL HA mIPNs were not observed. At day 10, there 
is a progressive increase in the levels of GFAP corresponding to the decreasing HA content. However, significant 
differences in mean values were only observed between the 0 mg/mL HA and the 2 mg/mL HA mIPNs. The GFAP 
expression in the 0 mg/mL HA mIPN was increased by 2.0 and 1.6-fold relative to 2 mg/mL HA (p < 0.000) and 
1 mg/mL HA (p = 0.004) formulations respectively. Our results and observations for the relative expression of 
GFAP as a function of HA content are in agreement with previously reported  literature53,54. The expression of 
the reactive marker S100β showed a very dynamic pattern (Fig. 6C). At day 3, S100β levels were 1.3-fold and 
1.7-fold higher in the 1 mg/mL HA formulation relative to the 2 mg/mL HA mIPN and the 0 mg/mL HA mIPN 
Figure 4.  Phenotypical evaluation of human astrocytes using qRT-PCR. Relative expression of ALDH1L1 (A), 
relative expression of GLAST (B), relative expression of GFAP (C), and relative expression of S100β (D).
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(p ≤ 0.019). Moreover, HAf in the 0 mg/mL HA mIPN exhibited 1.3-fold and 1.7- fold lower S100β levels rela-
tive to the other two experimental groups (p ≤ 0.019). Differences across groups in S100β initially observed at 
the early time point disappeared after 10 days in culture. Mean values across sample groups for the S100β levels 
after 10 days in culture were statistically indistinguishable (p ≥ 0.174).
Astrocytes also contribute the inflammatory response in CNS tissue. To evaluate the effects of the reduction 
in HA on the inflammatory response, HAf were stained for 3 inflammatory markers: iNOS (Fig. 7A,B), IL-1β 
(Fig. 7C,D) and TNFα (Fig. 7E,F). These markers are key regulatory cytokines in the inflammatory response of 
human  tissue51,52. As it is shown in Fig. 7 the trend for the inflammatory response at each time point was very 
similar for all three markers. After 3 days in culture, HAf in the 1 mg/mL HA mIPN exhibited higher levels of 
iNOS, IL-1β and TNFα relative to the other two formulations. Relative to the 2 mg/mL HA mIPN formulation, 
the protein levels in the 1 mg/mL HA mIPN were increased by 13.4-fold, 2.9-fold and 2.3-fold (p < 0.001) for 
iNOS, IL-1β and TNFα respectively. Similarly, the expression of iNOS, IL-1β and TNFα was 2.5-fold, 1.4-fold 
and 1.5-fold higher in the 1 mg/mL HA group when compared with the levels of the inflammatory markers in 
the 0 mg/mL HA mIPN (p ≤ 0.005). In comparison with day 3 results, at day 10, the levels of the three inflam-
matory markers increased progressively with the decrease in HA content (Fig. 7A,C,E). The expression of iNOS 
(Fig. 7A) in the 0 mg/mL HA group was 9.0-fold and 1.7-fold higher than in the 2 mg/mL (p < 0.001) and 1 mg/
mL HA mIPNs (p = 0.079) respectively. Furthermore, the levels of iNOS in the 1 mg/mL HA formulation were 
significantly elevated relative to 2 mg/mL mIPN (p = 0.043). In terms of IL-1β expression, its normalized levels 
(Fig. 7C) were increased from 0.22 in the 2 mg/mL HA formulation to 0.7 and 1.0 in the 1 mg/mL HA and 
0 mg/mL HA mIPNs respectively (p < 0.001). Finally, a similar trend was observed for the expression of TNFα 
(Fig. 7E) which was increased by a factor of 1.4 for 1 mg/mL HA and 2.5 factor for 0 mg/mL HA mIPNs when 
compared with the 2 mg/mL HA experimental group (p ≤ 0.001). We hypothesize that the increase in culture time, 
accentuates the differences in the inflammatory response among groups in the day 10 relative to the day 3 time 
point. The initial stress of the cells during the encapsulation process could have also impacted the expression of 
the inflammatory markers at day 3. Cumulatively, the expression of inflammatory cytokines in HAf is enhanced 
with the reduction in HA in the proposed engineered scaffolds. The upregulation of these inflammatory markers 
Figure 5.  Semi-quantitative analysis of the immunostaining results for the protein expression of the HAf 
quiescent markers ALDH1L1 and GLAST (A,C). Representative immunofluorescent images of the ALDH1L1 
and GLAST staining (B,D). The scale bar represents a distance of 100 µm. *Significantly different from 2 mg/mL 
HA, p < 0.05.
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have been previously observed in astrocytes exposed to the presence Aβ55. These findings are very significant 
since they suggest that the reduction in HA content in the absence of changes in scaffold modulus elicits an 
inflammatory response similar to that in astrocytes exposed to key biochemical molecules associated with the 
progression of neurodegenerative diseases.
To gain insight on a possible mechanism regulating astrocyte response to different levels of HA-HMW, 
the relative expression of the cell receptor HCAM was evaluated at the protein expression level (Fig. 7G,H). 
The upregulation of this cell marker has been associated with astrogliosis and the increase in the inflamma-
tory response of  astrocytes56–58. Furthermore, high expression of HCAM has been observed in astrocytes from 
Alzheimer  patients59. In our model, we observed that after 3 days in culture and relative to the 2 mg/mL HA 
group, the expression of HCAM was 1.7-fold and 1.3-fold higher in the 1 mg/mL and 0 mg/mL HA formula-
tion respectively, these differences were statistically significant (p ≤ 0.010). Moreover, the expression of HCAM 
in the 1 mg/mL group was 1.3-fold higher than in the 0 mg/mL HA formulation (p = 0.002). The trend for the 
relative expression of this marker at day 3 follows closely the trend observed for the expression of the selected 
inflammatory markers. This observation indicates that perhaps initially, HCAM is the primary receptor involved 
in the inflammatory signaling pathway in our model. After 10 days in culture, the expression of HCAM in the 
1 mg/mL formulation is 1.3-fold higher relative to the other two groups. Relative to the 2 mg/mL HA and 0 mg/
mL HA the p values for the comparison were p = 0.001 and p < 0.001 respectively. Differences in the expression 
of this receptor between the 2 mg/mL HA and the 0 mg/mL were not statistically significant (p = 0.684). Since 
HA can also interact with other receptors including the Toll-Like Receptors 2 and 4 (TLR-2, TLR-4), and the 
Hyaluronan-Mediated Motility Receptor (HMMR) it is possible that the inflammatory signaling depends on 
multiple routs and that different HA receptors may be activated at different time points. Given the current infor-
mation we cannot clearly present a possible controlling signaling pathway for the biological responses of human 
astrocyte cultured in our proposed mIPN based platform.
Figure 6.  Semi-quantitative analysis of the immunostaining results for the protein expression of the HAf 
reactive markers GFAP and S100β (A,C). Representative immunofluorescent images of the GFAP and S100β 
staining (B,D). The scale bar represents a distance of 100 µm. *Significantly different from 2 mg/mL HA, 
p < 0.05: #Significantly different from 1 mg/mL HA, p < 0.05.
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Figure 7.  Semi-quantitative analysis of the immunostaining results for the protein expression of the 
HAf inflammatory markers iNOS, IL-1β, TNFα and the cell receptor HCAM (A,C,E,G). Representative 
immunofluorescent images of the iNOS, IL-1β, TNFα and the cell receptor HCAM staining (B,D,F,H). The scale 
bar represents a distance of 100 µm. *Significantly different from 2 mg/mL HA, p < 0.05: # Significantly different 
from 1 mg/mL HA, p < 0.05.
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Conclusions
In this work we demonstrated that the proposed mIPN platform can be used to study the effects of composi-
tional changes in HA levels on HAf morphology and phenotype. We specifically illustrated that in the absence 
of significant changes in mechanical performance of the scaffolds, the decrease in HA concentration—which is 
normally associated with tissue degradation—is a significant contributing factor for an increase in the reactive 
and inflammatory response of human astrocytes. Overall, the reduction in HA content contributes to the decrease 
in total processes length of human astrocytes at least within the range of explored HA-HMW concentrations and 
experimental conditions. Furthermore, the expression of quiescent markers is attenuated as the HA concentration 
in the scaffolds is reduced while the expression of reactive and inflammatory markers is significantly upregulated. 
We recognize that the current work does not address all variables involves in the degradation process of HA. 
However, this work demonstrates that our mIPN platform has the potential to be tuned to explore the effects of 
different HA molecular weights and the presence of small soluble HA fragments on the biological response of 
human astrocytes while maintaining mechanical performance similar to those in native tissue. We also believe 
that in the future, this family of scaffolds could be potentially used as a human tissue disease model to evaluate 
effectiveness of therapeutic molecules on the regulation of the inflammatory responses of human astrocytes in 
3D contexts.
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